FDA on Nanotech, before the US House of Reps

Saturday, September 23, 2006

FDA associate commissioner explained the activities of Nanotechnology Environmental and Health Implications (NEHI) Working Group to the US' House of Representative's Comittee on Sciences over the past two years:
  1. communication by participating regulatory agencies concerning their respective statutory authorities for regulating nanoproducts, and their approaches for carrying out those authorities;
  2. encouraging all the participating regulatory agencies to develop a position statement on how they are addressing nanotechnology (an effort that has resulted in the establishment of a nanotechnology website at most of the participating regulatory agencies);
  3. development of a preliminary “risk assessment influence diagram” to help guide the NEHI Working Group’s approach to thinking about potential risks from nanoproducts and services (this effort led to a peer-reviewed scientific publication);
  4. discussion with various relevant standards bodies regarding nomenclature and standards development for nanotechnology that will affect both regulators and researchers; and
  5. compiling the inputs from participating agencies on their perceived needs for Environmental, Health, and Safety (EHS) research and information and development of a draft document drawn from this compilation and inputs from industry and other similar documents from other countries and organizations.

A product of these activities is a report titled Environmental, Health, and Safety Research Needs for Engineered Nanoscale Materials.

And the following groupings within NEHI:
  1. Instrumentation, metrology, and analytical methods
  2. Nanomaterials and human health
  3. Nanomaterials and the environment
  4. Health and environmental surveillance
  5. Risk management methods